No retraction, correction or concern found when last checked on Oct 16, 2026.

Liposomes: structure, composition, types, and clinical applications

Hamdi Nsairat, Dima Khater, Usama Sayed and 3 more

Heliyon · 2022 · Review · CC BY

doi:10.1016/j.heliyon.2022.e09394

Abstract

Liposomes are now considered the most commonly used nanocarriers for various potentially active hydrophobic and hydrophilic molecules due to their high biocompatibility, biodegradability, and low immunogenicity. Liposomes also proved to enhance drug solubility and controlled distribution, as well as their capacity for surface modifications for targeted, prolonged, and sustained release. Based on the composition, liposomes can be considered to have evolved from conventional, long-circulating, targeted, and immune-liposomes to stimuli-responsive and actively targeted liposomes. Many liposomal-based drug delivery systems are currently clinically approved to treat several diseases, such as cancer, fungal and viral infections; more liposomes have reached advanced phases in clinical trials. This review describes liposomes structure, composition, preparation methods, and clinical applications.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 16, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Drug delivery systems (DDSs) offer the potential to enhance the therapeutic index of drugs by increasing the drug concentration, the residence time in target cells and minimizing the side effects. DDSs involve delivering the potentially active drug to the site of action via a nano-vehicle to enhance the pharmacological properties of free drugs and cover their undesirable features through improving drug pharmacokinetics and biodistribution, as well as acting as drug reservoirs. These nanoparticles (NPs) usually ranged from a few nanometers to several hundred nanometers according to their intended application. Different natural, organic and inorganic materials are used to create NPs including ceramic, polymers, metals, and lipids that generate nanoparticles like micelles and liposomes.

2Therapeutic drugs are incorporated into the NPs mainly by physical interactions including, entrapment, surface attachment, or encapsulation. These variations and unique properties of different NPs could be used to improve the characteristics of traditional therapeutics. Nanomedicine facilitates designing novel therapeutic options in the nanoscale range to deliver a variety of active biomedical ingredients for the treatment, prevention, and diagnosis of many diseases.

3Despite the fast progress in this field, most nanoparticles-based drug delivery systems show improper loading capacity with a lack of specificity against their targets. As a result, the promising advances in the drug delivery systems should involve designing high and regulated capacity nanocarriers functionalized by recognition ligands that target specifically unique or overexpressed biomarkers. Liposomes are the most explored nanocarriers used in targeted drug delivery systems. Liposomes are spherical lipid vesicles (usually 50–500 nm in diameter particle size) composed of one or more lipid bilayers, as a result of emulsifying natural or synthetic lipids in an aqueous medium (Figure 1). Liposomes were firstly discovered in the 1960's by Bengham and later became among the most expansive drug delivery systems. Liposomes nanoemulsions are widely used nanoparticles in nanomedicine mainly due to their biocompatibility, stability, ease to synthesize and high drug loading efficiency, high bioavailability, and their safe excipients used in these formulations. Due to their size, hydrophobic and hydrophilic characteristics and their ability to encapsulate drug molecules either in the aqueous interior of the vesicles or in the lipophilic membrane, liposomes are considered promising to be used effectively as drug delivery systems. Several liposomal-based drug delivery systems have been approved by Food and Drug Administration (FDA) for disease treatment in the market. Moreover, liposomes are suitable for diagnostic and therapeutic applications using several routes of administration, including ocular, oral, pulmonary, transdermal, and parenteral. Liposomes are primarily created from phospholipids such as soybean phosphatidylcholine or synthetic dialkyl or trialkyl lipids. Incorporation of cholesterol into liposomes is indispensable since cholesterol modulates membrane permeability, changes fluidity, and improves the stability of bilayer membranes in the presence of biological fluids such as blood and plasma. Liposomal formulations may also contain polymers, and even membrane protein to prolong their circulation half-life, improve the biodistribution profile and enhance the encapsulated drug effectiveness Moreover, Stealth stabilized liposomes, incorporating phospholipids-attached polyethyleneglycol (PEG) into liposomes infrastructure, has been shown to be a useful method for modifying liposomes pharmacokinetic properties and biodistribution profiles. The current review describes liposomes compositions, types, methods of preparation, and clinical applications.

Liposomes

4According to the liposomes structures, they are classified into four categories based on size and number of bilayers: small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), multilamellar vesicle (MLV), and multivesicular vesicles (MVV). Liposomes have mono phospholipid bilayer in a unilamellar structure, while they have an onion-like structure in a multilamellar structure. MVV form a multilamellar arrangement with concentric phospholipid spheres as many unilamellar vesicles are produced within larger liposomes. Liposome encapsulation efficiency increases with liposome size and decreases with the number of bilayers for hydrophilic compounds only. The size of the vesicles is an important factor that controls the circulation half-life of liposomes. Both the size and number of bilayers influence the amount of the encapsulated drug. When liposomes are employed for drug delivery, the desired vesicles usually extend from 50 nm to 150 nm. Liposomes interaction with the cell membrane is represented by various theories: specific (modified with receptor-mediated) or nonspecific endocytosis, local fusion (adhesion), phagocytosis, and absorption into the cell membrane. Liposome-cell interactions are influenced by a variety of factors, including composition, the diameters of liposomes, surface charge, targeting ligand on the liposome surface, and biological environment.

Lipids and phospholipids used for liposomes

5Structurally, liposomes are spherical or multilayered spherical vesicles made by the self-assembly of diacyl-chain phospholipids (lipid bilayer) in aqueous solutions. The bilayer phospholipid membrane has a hydrophobic tail and a hydrophilic head that leads to the formation of an amphiphilic structure. Liposomes can be made from both natural and synthetic phospholipids. Lipid composition strongly affects liposome characteristics that include: particle size, rigidity, fluidity, stability, and electrical charge. For example, liposomes formulated from natural unsaturated phosphatidylcholine, as egg or soybean phosphatidylcholine, provide highly permeable and low stable properties. Though, saturated-phospholipids-based liposomes such as dipalmitoyl phosphatidylcholine led to rigid and almost impermeable bilayer structures.

6The hydrophilic group in the lipids may be negatively, positively charged, or zwitterionic (both negative and positive charge in the same molecule). The charge of the hydrophilic group provides stability through electrostatic repels. The hydrophobic group of lipids varies in the acyl chain length, symmetry, and saturation. The lipids that used in liposomes preparation may be classified as:

Natural lipids

7The membrane bilayer of normal cells are mainly composed of glycerophospholipids. Phospholipids are consist of a glycerol unit that is bonded to a phosphate group (PO42−) and to two fatty acid molecules. The phosphate group can be also bonded to small, essential choline organic molecule (Figure 2A). Natural phospholipids can be obtained from various sources such as soya bean, egg yolk. Phospholipids are classified as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), phosphatidylglycerol (PG), and phosphatidic acid (PA) regarding to the polar head groups. Natural phospholipids are less stable than synthetic phospholipids in liposomes preparation due to the unsaturated characteristics of the hydrocarbon chain (Figure 2). Natural phospholipids composed of a variety of fatty acids, one is a saturated fatty acid as palmitic acid (hexadecanoic acid, H3C-(CH2)14-COOH); margaric acid (heptadecanoic acid, H3C-(CH2)15-COOH) and the other is an unsaturated fatty acid (here oleic acid, or 9Z-octadecenoic acid that identified in egg yolk lecithin. The egg derived phospholipids and PCs are made of these fatty acids patterns: palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), and arachidonic acid (C20:4). These fatty acids are account for about 92% of the total fatty acid composition with a typical presence of the polyunsaturated fatty acids C 20:4 (n-6) and C22:6 (n-3) in egg phospholipids. Egg PC contains about 40% 1-palmitoyl-2-oleoylphosphatidylcholine. The principal saturated acid was stearic in PE and PS, and palmitic in the other lipids. Furthermore, the fatty acid pattern of the soybean derived account for about 95% palmitic acid (C16:0), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), and linolenic acid (C18:3). Since the unsaturated fatty acids of PE, PS, and PC amounted to over 50% of the total acids, they must occur at both the α- and β-positions of the glycerol moiety of these phospholipids.

Synthetic lipids

8Synthetic phospholipids are made by specific chemical modifications to the non-polar and polar regions of the natural phospholipids. The modification enables an unlimited variety of well-defined and categorized phospholipids. The major saturated synthetic phospholipids are based on either using stearic and/or palmitic fatty acid. Figures 3 and 4 represent different possible and commercial, synthetic, and saturated phospholipids usually used to prepare liposomes.

9Additionally, Synthetic phospholipids can be made from mixed fatty acids, unsaturated fatty acids in both hydrocarbons or only in one hydrocarbon chain (Figure 5).

Steroid

10Steroid are hydrophobic lipids consists of four-ring structure as shown in Figure 6. Steroid's diversity comes from the various functional groups attached to those rings. Cholesterol is the major steroid usually used in liposomes preparation in a ratio less than 30 % of the total lipids to improve liposomes rigidity and stability since its incorporated in the liposomes lipid bilayer. In a comparative study for cholesterol and β-Sitosterol effect on the liposome membrane features, they found that both steroids reduce liposomes membrane fluidity, increase absolute zeta potential, cause significant changes in particle size, and decrease DPPC phase transition temperature (Tm) and enthalpy.

Surfactants

11Surfactants were utilized in liposomes formulations to modify the encapsulation and release properties of liposomes through surface tension reduction between different immiscible phases. Surfactants are single acyl-chain amphiphiles that destabilize the lipid bilayer of liposomal nanoparticles (Figure 7), thus increasing nano-vessel deformability. Commonly utilized surfactants in liposomes formulations are: sodium cholate, Span 60, Span 80, Tween 60, and Tween 80. Various surfactants-containing liposomes have been widely used as a carrier in drug delivery to enhance skin penetration of encapsulated therapeutic agents. Ultra deformable liposomes, also called transfersomes, are a Surfactants-based nanovesicles with positive findings in transdermal drug delivery. The key factor making liposomes deformable is edge activator (surfactant). The edge activator can alter the lipid bilayers of vesicles increasing the deformability of them. These nanovesicles are different from conventional liposomes in which they can respond to osmotic pressure by rapid shape transformations only by low energy. Moreover, ultra deformable liposomes showed an increased in the drug transepidermal flow made them more suitable nanovehicle for the topical administration of antihypertensives.

Liposomes types

12Based on their compositions and applications, liposmes can be classified into conventional liposomes, charged liposomes, stealth stable liposomes, actively targeted liposomes, stimuli-responsive liposomes, and bubble liposomes.

Conventional liposomes

13These liposomes were synthesized from natural or synthetic phospholipids with or without cholesterol as a liposomes first generation. Cholesterol was added to improve liposomes fluidity, altering the bilayer rigidity and liposomes stability. Wu et al hat revealed that liposomal membrane rigidity decreased with the addition of cholesterol into a liposomes composed of hydrogenated soybean phospholipids (HSPC) and DSPE-PEG2000. Moreover, liposomes with some rigidity showed excellent tumor penetration and enhanced anti-tumor activity. Kaddah et al investigated the cholesterol content on the permeability and fluidity of DPPC liposome membrane. High cholesterol concentration increased the average liposomes size accompanying with a shape transition from irregular to nanosized, regular and spherical vesicles. In addition, cholesterol induced a decrease in the bilayer fluidity and modulating the release of hydrophilic molecules from lipid vesicles. Jovanović et al reported that increasing cholesterol content in the liposomes decreased the fluidity and enhanced the rigidity of liposomal membranes. They verified that a stable liposome should have an optimal 50 mol %. concentration of cholesterol to obtain and an appropriate membrane fluidity. As a result, cholesterol plays a crucial role in liposomes bilayer fluidity and rigidity, but these properties affected by the cholesterol molar ratio with types of phospholipids used along with the nature of the encapsulated drug. Conventional liposomes showed a short blood circulation time due to their susceptability to elimination by the mononuclear phagocyte system with rapid accumulation in liver and spleen. Hence, MPS obstructs the delivery of conventional liposomes to the target region and restricts their distribution to other tissues of the body. Conventional liposomes also showed relatively limited stability in vitro. As a result, stealth stable liposomes were invented to increase blood circulation and enhanced in vivo liposomes stability.

Charged liposomes

14Oleic acid and N-[1(2,3-dioleoyloxy) propyl]-N,N,N-trimethylam-monium chloride (DOTAP) are usually used to prepare anionic and cationic liposomes, respectively. Charged liposomes showed higher liposomal stability during the storage, as charged particles repel each other and reduce aggregation abilities. Cationic liposomes are used in gene therapy due to their ability to successfully encapsulate nucleic acids by electrostatic attractions.

15Cationic liposomes are suitable for delivering various negatively charged macromolecules such as DNA, RNA, and oligonucleotides because their negative charge and rather a large size restrict their passive diffusion into cells. Cationic liposomes also selectively target angiogenic endothelial cells in tumors. Cationic liposomes are considered a potential tool for delivering therapeutics to the brain. Cationic liposomes can cross the BBB by receptor-mediated transcytosis or absorptive-mediated transcytosis. The higher positive charge on the surface of cationic liposomes may affect their blood circulation and lead to due to electrostatic interactions with anionic species in the blood and increase liposomes aggregation that reduces their localization site of action. Decorating the surface of these liposomes with poly ethylene glycol (PEG) protects the them from the circulating proteins, improving the drug efficiency through improving systemic circulation time and decrease immunogenicity.

16Anionic liposomes are less stable in the bloodstream than neutral and cationic liposomes; they showed a higher clearance rate. Anionic liposomes are usually utilized for transdermal drug delivery because they improve penetration properties through the stratum corneum of the skin.

Stealth stabilized liposomes

17These second-generation liposomes are characterized by surface decoration with synthetic polymers, glycoproteins, polysaccharides, or specific receptors ligands to achieve narrowed distribution, and accumulation at the intended site. Huayluorinic acid, polyvinyl alcohol (PVA), and polyethylene glycol (PEG)) were considered the best model for liposome steric protection. PEGylated liposomes are denoted as stealth liposomes. Doxil® was the first successful pegylated liposome-based product. Stealth stabilized liposomes showed longer circulation time, leading to a better target accumulation than conventional liposomal drugs.

Actively-targeted liposomes

18Actively-targeted liposomes represent third-generation liposomes. Liposomes' active targeting increases the selectivity of liposome interaction with diseased cells and triggers receptor-mediated endocytosis of the liposome and its payload into the desired cellular target.

19Many liposomes nanocarriers have been approved for anti-tumor agents delivery by passive ways based on the enhanced permeability and retention (EPR) effect of cancerous cells. Passive targeting does not discriminate between normal and diseased cells; therefore, cell-specific targeting liposomes have been developed to increase the accumulation and localization of anti-tumor agents in diseased cells. Liposomes targeting can be enhanced by incorporating molecular recognition moieties, which can lead to drug transport with better efficacy and low side effects. For example, liposomal targeting strategies have utilized simple peptides, proteins (including antibodies) or protein fragments, carbohydrates, nucleic acids, or vitamins.

20Both active (ligands-conjugated) and passive (‘non’-conjugated) targeted liposomes are distributed to target cells via the same passive distribution mechanism. The field of ligand-targeted liposomes has expanded rapidly despite that several non-targeted liposomes have reached the clinic or in clinical trials.

21New efforts in targeted drug delivery systems utilize polyunsaturated fatty acids, folic acid, hyaluronic acid, or oligopeptides as tumor recognition moieties. These ligands encounter many discussion fields around their affinity and specificity with no detailed mechanism of tumor-targeting accompanied to limited success for certain small ligands, besides the enzymatic degradation in the systemic circulation, making them inappropriate for many in vivo studies. Recently, aptamers and aptamer-functionalized nanoparticles high affinity and specificity have great attention in targeted drug delivery systems.

22Active targeting of the nanocarriers can be achieved through non-covalent or covalent conjugation of targeting ligands to the drug molecule or to the surface of nanocarrier to bind the overexpressed targeting biomarkers selectively on the tumor cells. The direct conjugation of drugs to the targeting ligand can disrupt the receptor/ligand recognition and may alter the drug efficacy. Nano-carrier active targeting enables drugs to be localized within the action site with higher effectiveness to reduce drug dose, minimize the drug side effects and reduced drug variation in blood concentration. Stealth and conventional liposomes usually showed a slow release of the loaded drugs and failed fusion with the endosome after internalization. Consequently, stimuli-responsive liposomes have been introduced to overcome these challenges.

Stimuli-responsive liposomes

23Stimuli-responsive liposomes are smart liposomal systems that display rapid release of their drug payload upon physicochemical or biochemical stimuli, such as pH, temperature, redox potentials, enzymes concentrations, ultrasound, electric or magnetic fields.

24Stimuli-responsive liposomes should contain a certain constituent that controls the lipid bilayer's stability and permeability. There are two basic kinds of inductions, remote and local. Remote inductions respond to outside stimuli including, heat, magnetic field, light, electric field, and ultrasounds. Local triggering releases respond to stimuli inside the target tissues, such as pH, redox potential, and enzymes. Table 1 represents the most common stimuli-responsive liposomes that respond to specific triggers that lead to a controlled release nanosystem, enhanced intracellular distribution.

Bubble liposomes

25Bubble liposomes (gas-encapsulated liposomes) are expected to create new applications in the field of gene delivery and drug delivery systems. Recently, liposomes have been used to encapsulate bioactive gases and/or drugs for ultrasound-controlled drug release with enhanced drug delivery. Nitric oxide (NO) bubble liposomes offer a distinguishing NO intravenous therapeutics option overcome common microbubbles, in which liposomes shield NO from hemoglobin rummaging in vitro as usually occurred by free NO. Oxygen bubble liposome (OBL) enables high oxygen fixations with high pO2 conditions of the lungs. This separates OBL from great fluorocarbon and hemoglobin-based oxygen transporters and keeps their utilization as supported oxygen conveyance stages.

Methods of preparation

26Liposomes can be formulated using different approaches. The process of liposome manufacture and the phospholipids type critically affects the final liposomes characteristics. Liposome's fabrication procedures can be classified into:

Thin film hydration method (Bangham method)

27In this method, all lipids and the hydrophobic drug are dissolved in suitable organic solvent using a round-bottom flask. The organic solvent then evaporated gently under reduced pressure to create a thin film layer. The obtained thin film is then hydrated, at above the transition temperature (Tm) of the used lipid, with an aqueous buffer solution. The hydration solution may contain a hydrophilic drug/s to be loaded into the liposomes aqueous core. The rate of hydration determines the efficiency of drug encapsulation, which the slower the rate of hydration, the higher the encapsulation efficiency. Liposomes resizing, lamellarity types and particles distributions may be controlled by either extrusion through a polycarbonate membranes of specific pore sizes or the use of bath or probe sonicators. Extrusion method ensures stable liposomes with more encapsulation efficiency over sonication. Sonication usually produce SUVs liposomes and may also degrade or hydrolyze encapsulated drugs and/or lipids. Probe sonication may subject liposomes suspensions to potential metal contamination (Figure 8).

Reverse-phase evaporation method

28The reverse-phase evaporation method is usually used as an alternative to thin-film hydration by forming a water-in-oil emulsion. First, the lipids are dissolved in an organic solvent which is then directly mixed with an aqueous buffer containing the hydrophilic drug. The organic solvent then evaporated under a reduced pressure rotary evaporator leading to form lipid vesicles dispersed in the aqueous solution. The average size and polydispersity of the preformed vesicles can be reduced by extrusion. This method is suitable for high molecular weight molecules, but therapeutic peptides may be denatured due to organic solvents and to sonication conditions.

Solvent injection methods

29The injection methods were classified according to the type of organic solvent used (Figure 9). An organic solvent dissolving the lipids and the hydrophobic active agents were rapidly injected into an aqueous phase. Diethyl ether enable direct solvent evaporation during mixing process at a temperature above to the boiling point of the used solvent. Utilizing ethanol for injection required a 10-to-20-fold aqueous solution and ethanol can be evaporated under vacuum using a rotary evaporator, dialysis, or filtering. This method mostly prepared liposomal formulations with higher polydispersity indexes (PDI). In addition, continuous exposure to high temperature and organic solvent might reduce drug and lipids stability.

Detergent removal method

30In this method, lipids and a high critical micelle concentration (CMC) surfactant were dissolved in a suitable organic solvent using a round bottom flask. A thin film was obtained at the bottom of the flask after solvent gentle evaporation. A mixed micelles solution then obtained by hydrating the lipid film in an aqueous solution containing the drug molecules. The surfactant is then removed by dialysis, size-exclusion chromatography, adsorption onto hydrophobic beads or dilution. Finally, a LUVs liposomes vesicle will be formulated after solution concentration. A main drawback of this method is that most hydrophilic drugs are separated from the liposomes during detergent removal step.

Dehydration-rehydration method

31It is an organic solvent free method to produce LUVs using sonication. This method based on direct dispersing of the lipids at low concentrations into an aqueous solution containing the drug molecules followed by sonication. First, the dehydration step to evaporate water under nitrogen to create multilayered film entrapping the drug molecules. Then, a hydration step to form large vesicles encapsulating the drug molecules. This method is simple but with high heterogeneity of the liposomes sizes.

Heating method

32It is also an organic solvent free technique. In this method, lipids are hydrated directly with aqueous solution, and heated for not less than one hour above the Tm of the used phospholipids in the presence of a 3–5 % hydrating agent as glycerin or propylene glycol. The suspension can be heated up to 100 °C when adding cholesterol to the formulation. The hydrating agents act as a stabilizer and isotonizing additives that prevent nanoparticle coagulation and sedimentation. Moreover. The hydration agents provide a cryoprotective effect that makes the heating method an efficient method for the formulation of powder inhalable liposomes.

pH jumping method

33Another solvent-free method for liposomes preparation is the pH jumping method. In this method, the aqueous solution of phosphatidic acid and phosphatidylcholine are exposed to almost four-fold increase in pH over a short time to break down MLVs into SUVs. The ratio of phosphatidic acid: phosphatidyl choline determine the percentage of SUVs versus LUVs produced.

Microfluidic channel method

34The microfluidic channel method (Figure 10) has been recently proposed as a novel method for liposomes preparation. Microfluidics provides a tool to employ liquids within microscopic channels. In this method, lipids are dissolved in ethanol or isopropanol, and the resultant solution is injected upright or in the opposite direction to the aqueous medium within the micro-channels. This method involves continuous axial mixing of the organic and aqueous solutions leads to liposomes formation. Liposomes are stabilized using surfactants to avoid coagulation and separation. Microfluidic channel methods control the mixing process of organic and aqueous phases to achieve reproducible liposomes with proper average size, polydispersity, morphology, and lamellarity.

Supercritical fluidic method

35This method utilized a supercritical fluid, carbon dioxide (CO2), to dissolve lipids instead of using organic solvents. A high-performance liquid pump provides a continuous flow of the aqueous phase into a cell that contains the supercritical lipid solution, allowing phase transition of the dissolved phospholipids. Upon abrupt decrease in pressure, liposomes will formed after completely removing of CO2. 5-fold higher encapsulation efficiencies were obtained by this method. This method suffers from high cost, low yield, and special infrastructures even with using the environmentally safe and cheap carbon dioxide.

Freeze-thaw cycles

36This technique is usually used during liposomes preparations to increase the encapsulation efficiency and to enhance liposome lamellarity. This approach utilized a freeze-thaw cycles between -196 °C in liquid nitrogen and below the transition temperature of the used phospholipids lipids.

Freeze-drying (lyophilization)

37This treatment is applied to preserve the liposomal products and improve their shelf stability. Freeze-drying involves deep freezing of the liposomes suspension after mixing with a cryoprotective, mainly 5–10 % sucrose or trehalose. Then, a sublimation step at very low temperature and a reduced vacuum was applied to convert the liquid samples to fluffy solid particulates. Lyophilization becomes essential treatment for liposomes encapsulating thermo-sensitive biomolecules.

Liposomes characterization

38Liposome physiochemical characterization include average size and size distribution (or polydispersity index (PDI)), surface charge (or Zeta potential), shape and morphology, lamellarity, encapsulation efficiency, phase behavior (or polymorphism) and in vitro release profile (Table 2).

Liposomes drug loading

39Liposomes drug loading can be attained by passive or active approaches. Passive loading entraps hydrophilic drug in the liposomes aqueous core during lipid bilayer formation, while hydrophobic drugs accumulate in the small-sized hydrophobic lipid bilayer. Passive loading suffers from bilayer destabilization, high drug/lipid ratio, and rapid drug release. Therefore, improving the aqueous solubility of these hydrophobic drugs by cyclodextrin host-guest complexation were successfully applied and permitliposomes aqueous core loading by forming drug-in-cyclodextrins-in-liposomes delivery system.

40Active or remote loading has been developed to ensure high encapsulation efficiency of precious chemotherapeutic agents. Remote loading can be achieved into preformed liposomes by pH gradient and/or potential ionic differences across liposomal bilayer membranes. The success of intraliposomal remote loading are govern by to main parameters, (i) drug aqueous solubility (ii) presence of an ionizable functional group in drug chemical.

41Intraliposomal active loading of hydrophobic drugs in response to ionic and/or pH gradients across the liposomes bilayer was developed. This procedure enables hydrophobic drugs to accumulate inside the liposomes core after the vesicles are created. The advantage of this method is that the loading of the drug can be performed independently of liposomes preparation conditions. Most potentially active drugs are weak bases possessing primary, secondary, or tertiary amine functional groups that can be loaded in response to pH gradients. Drugs that are not weak bases, or do not have an ionizable functional group, can be converted to weak base prodrugs or encapsulated with amino-modified carriers as cyclodextrins, therefore allowing encapsulation and intraliposomal retention.

Protein corona fingerprints of liposomes

42Liposomes have been used to overcome many problems associated with low efficiency of anticancer drugs. Recently, a concept is emerging that the limited success of liposomal drugs in clinical practice due to poor knowledge of liposomes behavior in vivo. Lipid vesicles are usually covered by plasma proteins in vivo forming a biomolecular coating, referred to as the protein corona (PrC). Recent studies verified that PrC fingerprints (PrCFs) enhanced liposome attachment with cancer cells, triggering efficient particle localization and internalization.

43Accordingly, enrichment in PrCFs was utilized to predict the targeting ability of synthesized liposomal formulations. Palchetti et al reported that the targeting capability of liposome–protein complexes clearly relate with cellular uptake in pancreatic adenocarcinoma (PANC-1) and insulinoma (INS-1) cells as quantified by flow-assisted cell sorting (FACS). The results showed that cellular uptake of the liposomal formulation with the highest abundance of PrCFs was much larger than that of Onivyde®, an Irinotecan liposomal drug approved by the Food and Drug Administration in 2015 for the treatment of metastatic Pancreatic ductal adenocarcinoma (PDAC). Furthermore, Digiacomo et al identified a potential protein biomarker for pancreatic ductal adenocarcinoma (PDAC) by utilizing liposomes to accumulate PrC coating layer from human plasma proteins. These targeting liposomes may be used for the early diagnosis of PDAC. This approach could open the interesting possibility to identify novel biomarkers for liposomes formulations in the context of personalized medicine.

Liposomes in clinical applications

44Various liposomal-based formulations were successfully implemented in clinical fields as antitumor, anti-fungal therapies, analgesics. Doxil® was the first approved clinical anticancer liposome drug in the USA (1995). It opened the way to several other liposomal formulations to get to the clinical application fields by innovating the pH gradient active loading and usage of PEGylation for stealth liposomes. Conventional liposome without PEGylation, can be attractive when circulation half-life is not the goal. DepoFoam™ is mostly used for gradual drug release, thus maintaining a continuous drug supply for long-lasting effect.

Cancer treatment

45Doxil® or Caelyx® was presented in 1995 by Sequus Pharmaceuticals. Doxil was designed as a polyethylene glycol coated doxorubicin (DOX) liposome intended for the treatment of Kaposi's sarcoma. LipoDox® is another FDA approved PEGylated liposomal formulation encapsulating DOX manufactured by Sun Pharma in 2012. Daunorubicin was the second anthracycline antineoplastic drug loaded in liposomes to treat acute myeloid leukemia (AML) under the generic name DaunoXome®. Myocet® is a non-PEGylated liposomes encapsulating DOX that showed a shorter circulation half-life with less cardiac side effects.

46Depocyt® consists of Citarabine, a cell-cycle cytotoxic drug, enclosed in the DepoFoam™ multivesicular enclosure, which allows a sustained two-week release. A new liposomes formulation called Mepact® was globally approved for the treatment of osteosarcoma. Vincristine also incorporated into sphingomyelin/cholesterol-based liposome under the name of Marqibo®. This approved formula offered longer circulation time without surface-modified, resulting in a higher accumulation in target tissues in which vincristine is gradually released. Onivyde® is another PEGylated liposome carrying irinotecan and exhibits a long-acting, antitumor effect. In addition, Vyxeos® also known as CPX-351, is composed of a combination of Cytarabine and daunorubicin, encapsulated in a liposome in a ratio of 5:1. This formulation reduced adverse effects with enhanced effectiveness. Finally, Paclitaxel, an anticancer drug, was also incorporated into Lipusu® liposomes to treat gastric carcinoma efficiently with much less adverse effects.

Fungal treatment

47A two major approved anti-fungal liposomes formulation were Ambisome® and Fungisome®. They encapsulate Amphotericin B anti-fungal drug with many advantages compared free drug. These Amphotericin B liposomes were stabilized in saline and have longer bioavailability and less toxicity and side effects.

Photodynamic therapy

48Visudyne®: is the only liposomal drug delivery agent approved for age-related macular degeneration therapy by inhibiting the generation of blood vessels in the eye.

Pain management

49DepoDur™ is a morphine formulation using DepoFoam™ Technology that resulted in a sustained release formula with prolonging the clinical effect time. Exparel® also uses the DepoFoam™ technology to release Bupivacaine for sustained pain relief gradually.

50Table 3 summarizes the different clinically approved liposomes formulations in terms of their purpose, lipid constituents, active ingredients, and administration route.

Liposomes in clinical trials

51From the 83316 active clinical trials registered, 511 liposomal clinical trials investigating liposomal products which are distributed worldwide as shown in Figure 11. The drugs being examined belong to anticancer drugs, analgesics, immune-modulators, anti-fungal, etc. Among these drugs, 121 of the 511 are in phase III testing, 236 are in phase II, 120 are in phase I, and 6 in early phase I.

Liposomes in vaccinations

52Liposome formulations could protect DNA/RNA and proteins payload from biodegradation. Furthermore, their transfection efficiency could be enhanced by modifying surface charge, size, and lipid structure. Two commercial vaccines based on virosome technology are currently on the market, Epaxal® and Inflexal® V (Berna Biotech Ltd, Bern, Switzerland), a hepatitis A vaccine. Virosomes are liposomal formulations that have viral envelope proteins anchored to their lipid membrane.

53Recently, COVID-19 mRNA based-vaccines utilized liposomes protection to increase their in vitro and in vivo stability. Liposome-based mRNA anti-COVID-19 vaccine has been designed by Pfizer/BioNTech and Moderna, and already administered worldwide. These vaccines were made to maintain the stability of liposomes in blood and to promote immune responses. Their components include distearoyl phosphatidyl choline and cholesterol that considered the main constituents of conventional liposomes. Four major ingredients were used in COVID-19 vaccines: Cationic lipids, for instance 1,2-dioleoyl-3 (trimethylammonium) propane (DOTAP), to binds to the negatively charged mRNA, pegylated lipids stabilize the particle, phospholipids and cholesterol molecules that form the required structure. These formulas encapsulate mRNA, protect it from nucleases, and deliver it into cells, where the mRNA is released and used to generate proteins. During COVID-19 pandemic, many liposome-based vaccines have been developed with great success. Accordingly, mRNA coding for the protein spike of the Coronavirus, would be encapsulated into liposomes that are designed to be stable in the circulating blood until they are taken up by phagocytic cells in the body by endocytosis. The mRNA will then be expressed as the spike protein in turn promoting an immune response to it that will kill or inactivate the invading virus.

Conclusion

54Liposomes were successfully utilized as an efficient drug delivery system for various diseases ranging from cancer treatment to pain managing. The biocompatible, biodegradable, and low immunogenicity liposomes formulation enhanced the pharmacokinetics and pharmacodynamics properties of water insoluble, poor bioavailable and highly toxic drug. Liposomes undergone numerous evolutions in terms of their constituents and manufacturing process to overcome their early limitations. Several liposomes formulation is currently approved in the market to treat various diseases and more than five hundred liposomal formulations are now in different phases of clinical investigation. Nevertheless, liposomes critical challenges are their physical and chemical stability. As a result, there are a n essential need to develop liposomes with high stability significantly impacts their clinical application. Thus, in silico simulation and computational investigations may enable approximate estimation for the best liposomal formulation in their constituents and 3-D structure morphology.

Author contribution statement

55All authors listed have significantly contributed to the development and the writing of this article.

Funding statement

56This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability statement

57No data was used for the research described in the article.

Declaration of interests statement

58The authors declare no conflict of interest.

Additional information

59No additional information is available for this paper.

References 226

1.
Kim B.Y., Rutka J.T., Chan W.C. Nanomedicine. N. Engl. J. Med. 2010;363:2434-2443.
Not in our library10.1056/nejmra0912273
2.
Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science. 2004;303:1818-1822.
Not in our library10.1126/science.1095833
3.
Khater D., Nsairat H., Odeh F., Saleh M., Jaber A., Alshaer W., Al Bawab A., Mubarak M.S. Design, preparation, and characterization of effective dermal and transdermal lipid nanoparticles: a review. Cosmetics. 2021;8.
Not in our library
4.
Yezhelyev M.V., Gao X., Xing Y., Al-Hajj A., Nie S., O'Regan R.M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer, the Lancet. Oncology. 2006;7:657-667.
Not in our library10.1016/s1470-2045(06)70793-8
5.
Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today. 2003;8:1112-1120.
Not in our library10.1016/s1359-6446(03)02903-9
6.
Nsairat H., Khater D., Odeh F., Al-Adaileh F., Al-Taher S., Jaber A.M., Alshaer W., Al Bawab A., Mubarak M.S. Lipid nanostructures for targeting brain cancer. Heliyon. 2021;7.
Not in our library10.1016/j.heliyon.2021.e07994
7.
Celia C., Paolino D., Santos H.A. Advanced nanosystems for clinical translation. Adv. Ther. 2021;4:2000215.
Not in our library
8.
Haley B., Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 2008;26:57-64.
Not in our library10.1016/j.urolonc.2007.03.015
9.
Doane T.L., Burda C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem. Soc. Rev. 2012;41:2885-2911.
Not in our library10.1039/c2cs15260f
10.
Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007;2:751-760.
Not in our library10.1038/nnano.2007.387
11.
Alshaer W., Hillaireau H., Fattal E. Aptamer-guided nanomedicines for anticancer drug delivery. Adv. Drug Deliv. Rev. 2018;134:122-137.
Not in our library10.1016/j.addr.2018.09.011
12.
Sun T., Zhang Y.S., Pang B., Hyun D.C., Yang M., Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. 2014;53:12320-12364.
Not in our library10.1002/anie.201403036
13.
Jha S., Sharma P.K., Malviya R. Liposomal drug delivery system for cancer therapy: advancement and patents. Recent Pat. Drug Deliv. Formulation. 2016;10:177-183.
Not in our library10.2174/1872211310666161004155757
14.
Advances and Challenges of Liposome Assisted Drug Delivery · 2015
No notice
15.
Noble G.T., Stefanick J.F., Ashley J.D., Kiziltepe T., Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32:32-45.
Not in our library10.1016/j.tibtech.2013.09.007
16.
Hafner A., Lovric J., Lakos G.P., Pepic I. Nanotherapeutics in the EU: an overview on current state and future directions. Int. J. Nanomed. 2014;9:1005-1023.
Not in our library10.2147/ijn.s55359
17.
McClements D.J., Rao J. Food-grade nanoemulsions: formulation, fabrication, properties, performance, biological fate, and potential toxicity. Crit. Rev. Food Sci. Nutr. 2011;51:285-330.
Not in our library10.1080/10408398.2011.559558
18.
Chen T., Gong T., Zhao T., Fu Y., Zhang Z., Gong T. A comparison study between lycobetaine-loaded nanoemulsion and liposome using nRGD as therapeutic adjuvant for lung cancer therapy. Eur. J. Pharmaceut. Sci. 2018;111:293-302.
Not in our library10.1016/j.ejps.2017.09.041
19.
Fathi S., Oyelere A.K. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? Future Med. Chem. 2016;8:2091-2112.
Not in our library10.4155/fmc-2016-0135
20.
Liposomal Formulations in Clinical Use: An Updated Review · 2017
No notice
21.
Liposome: classification, preparation, and applications · 2013
No notice
22.
Ebrahim S., Peyman G.A., Lee P.J. Applications of liposomes in ophthalmology. Surv. Ophthalmol. 2005;50:167-182.
Not in our library10.1016/j.survophthal.2004.12.006
23.
He H., Lu Y., Qi J., Zhu Q., Chen Z., Wu W. Adapting liposomes for oral drug delivery. Acta Pharm. Sin. B. 2019;9:36-48.
Not in our library10.1016/j.apsb.2018.06.005
24.
Mehta P.P., Ghoshal D., Pawar A.P., Kadam S.S., Dhapte-Pawar V.S. Technology, Recent advances in inhalable liposomes for treatment of pulmonary diseases: concept to clinical stance. J. Drug Deliv. Sci. Technol. 2020;56:101509.
Not in our library
25.
Pierre M.B.R., Costa I.d.S.M. Liposomal systems as drug delivery vehicles for dermal and transdermal applications. Arch. Dermatol. Res. 2011;303:607-621.
Not in our library10.1007/s00403-011-1166-4
26.
Barenholz Y.C.J. Doxil®—the First FDA-Approved Nano-Drug: Lessons Learned. J. Controll. Release. 2012;160:117-134.
Not in our library10.1016/j.jconrel.2012.03.020
27.
Cevenini A., Celia C., Orrù S., Sarnataro D., Raia M., Mollo V., Locatelli M., Imperlini E., Peluso N., Peltrini R., De Rosa E., Parodi A., Del Vecchio L., Di Marzio L., Fresta M., Netti P.A., Shen H., Liu X., Tasciotti E., Salvatore F. Liposome-embedding silicon microparticle for oxaliplatin delivery in tumor chemotherapy. Pharmaceutics. 2020;12.
Not in our library10.3390/pharmaceutics12060559
28.
Kirui D.K., Celia C., Molinaro R., Bansal S.S., Cosco D., Fresta M., Shen H., Ferrari M. Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response. Adv. Healthc. Mater. 2015;4:1092-1103.
Not in our library10.1002/adhm.201400738
29.
Sahoo S.K., Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov. Today. 2003;8:1112-1120.
Not in our library10.1016/s1359-6446(03)02903-9
30.
Hattori Y., Hu S., Onishi H.J. Effects of cationic lipids in cationic liposomes and disaccharides in the freeze-drying of siRNA lipoplexes on gene silencing in cells by reverse transfection. J. Liposome Res. 2020;30:235-245.
Not in our library10.1080/08982104.2019.1630643
31.
Laouini A., Jaafar-Maalej C., Limayem-Blouza I., Sfar S., Charcosset C., Fessi H.J. Biotechnology, Preparation, characterization and applications of liposomes: state of the art. J. Coll. Sci. Biotechnol. 2012;1:147-168.
Not in our library
32.
Liposomal Formulations in Clinical Use: An Updated Review · 2017
No notice
33.
Mori A., Klibanov A.L., Torchilin V.P., Huang L. Influence of the steric barrier activity of amphipathic poly (ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 1991;284:263-266.
Not in our library10.1016/0014-5793(91)80699-4
34.
Tadokoro S., Hirashima N., Utsunomiya-Tate N.J.B., Bulletin P. 2016;39:446-449.
Not in our library10.1248/bpb.b15-00751
35.
Pasut G., Paolino D., Celia C., Mero A., Joseph A.S., Wolfram J., Cosco D., Schiavon O., Shen H., Fresta M. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy. J. Contr. Release: Off. J. Controll. Release Soc. 2015;199:106-113.
Not in our library10.1016/j.jconrel.2014.12.008
36.
Mare R., Paolino D., Celia C., Molinaro R., Fresta M., Cosco D. Post-insertion parameters of PEG-derivatives in phosphocholine-liposomes. Int. J. Pharm. 2018;552:414-421.
Not in our library10.1016/j.ijpharm.2018.10.028
37.
Leitgeb M., Knez Ž., Primožič M. Sustainable technologies for liposome preparation. J. Supercrit. Fluids. 2020;165:104984.
Not in our library
38.
Influence of the Encapsulation Efficiency and Size of Liposome on the Oral Bioavailability of Griseofulvin-Loaded Liposomes · 2016
No notice
39.
Targeted Liposomal Drug Delivery to Monocytes and Macrophages · 2011
No notice
40.
Caracciolo G., Pozzi D., Caminiti R., Amenitsch H. Lipid mixing upon deoxyribonucleic acid-induced liposomes fusion investigated by synchrotron small-angle x-ray scattering. Appl. Phys. Lett. 2005;87:133901.
Not in our library
41.
Storm G., Belliot S.O., Daemen T., Lasic D.D. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 1995;17:31-48.
Not in our library
42.
Bozzuto G., Molinari A. Liposomes as nanomedical devices. Int. J. Nanomed. 2015;10:975.
Not in our library10.2147/ijn.s68861
43.
Düzgüneş N., Nir S. Mechanisms and kinetics of liposome–cell interactions. Adv. Drug Deliv. Rev. 1999;40:3-18.
Not in our library10.1016/s0169-409x(99)00037-x
44.
Lee K.D., Nir S., Papahadjopoulos D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry. 1993;32:889-899.
Not in our library10.1021/bi00054a021
45.
Kono K., Nakai R., Morimoto K., Takagishi T. Temperature-dependent interaction of thermo-sensitive polymer-modified liposomes with CV1 cells. FEBS Lett. 1999;456:306-310.
Not in our library10.1016/s0014-5793(99)00975-8
46.
Wu X., Dai X., Liao Y., Sheng M., Shi X. Investigation on drug entrapment location in liposomes and transfersomes based on molecular dynamics simulation. J. Mol. Model. 2021;27:111.
Not in our library10.1007/s00894-021-04722-3
47.
Liposomes: Structure, Biomedical Applications, and Stability Parameters With Emphasis on Cholesterol · 2021
Retracted
48.
Pavelić Z., Skalko-Basnet N., Jalsenjak I. Characterisation and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis. Int. J. Pharm. 2005;301:140-148.
Not in our library10.1016/j.ijpharm.2005.05.022
49.
Calvagno M.G., Celia C., Paolino D., Cosco D., Iannone M., Castelli F., Doldo P., Frest M. Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes. Curr. Drug Deliv. 2007;4:89-101.
Not in our library10.2174/156720107779314749
50.
Large D.E., Abdelmessih R.G., Fink E.A., Auguste D.T. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv. Drug Deliv. Rev. 2021;176:113851.
Not in our library10.1016/j.addr.2021.113851
51.
Daraee H., Etemadi A., Kouhi M., Alimirzalu S., Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif. Cell Nanomed. Biotechnol. 2016;44:381-391.
Not in our library10.3109/21691401.2014.953633
52.
Monteiro N., Martins A., Reis R.L., Neves N.M. Liposomes in tissue engineering and regenerative medicine. J. R. Soc. Interface. 2014;11:20140459.
Not in our library10.1098/rsif.2014.0459
53.
Li J., Wang X., Zhang T., Wang C., Huang Z., Luo X., Deng Y. A review on phospholipids and their main applications in drug delivery systems. Asian J. Pharm. Sci. 2015;10:81-98.
Not in our library
54.
Ramrakhiani L., Chand S. Assay Methods, Industrial Potential and Pathogenicity, Applied Biochemistry and Biotechnology. 2011;164:991-1022.
Not in our library10.1007/s12010-011-9190-6
55.
van der Veen J.N., Kennelly J.P., Wan S., Vance J.E., Vance D.E., Jacobs R.L. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim. Biophys. Acta Biomembr. 2017;1859:1558-1572.
Not in our library10.1016/j.bbamem.2017.04.006
56.
van Hoogevest P., Wendel A. The use of natural and synthetic phospholipids as pharmaceutical excipients. Eur. J. Lipid Sci. Technol. 2014;116:1088-1107.
Not in our library10.1002/ejlt.201400219
57.
Phospholipids of Animal and Marine Origin: Structure, Function, and Anti-Inflammatory Properties · 2017
No notice
58.
Briuglia M.L., Rotella C., McFarlane A., Lamprou D.A. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv. Transl. Res. 2015;5:231-242.
Not in our library10.1007/s13346-015-0220-8
59.
Jovanović A.A., Balanč B.D., Ota A., Ahlin Grabnar P., Djordjević V.B., Šavikin K.P., Bugarski B.M., Nedović V.A., Poklar Ulrih N. Comparative effects of cholesterol and β-sitosterol on the liposome membrane characteristics. Eur. J. Lipid Sci. Technol. 2018;120:1800039.
Not in our library
60.
Cipolla D., Wu H., Gonda I., Eastman S., Redelmeier T., Chan H.-K. Modifying the release properties of liposomes toward personalized medicine. J. Pharmaceut. Sci. 2014;103:1851-1862.
Not in our library10.1002/jps.23969
61.
Bozzuto G., Molinari A. Liposomes as nanomedical devices. Int. J. Nanomed. 2015;10:975-999.
Not in our library10.2147/ijn.s68861
62.
Lee E., Kim A., Oh Y.-K., Kim C.-K. Effect of edge activators on the formation and transfection efficiency of ultradeformable liposomes. Biomaterials. 2005;26:205-210.
Not in our library10.1016/j.biomaterials.2004.02.020
63.
Tian Y., Chen L., Zhang W. Influence of ionic surfactants on the properties of nanoemulsions emulsified by nonionic surfactants span 80/tween 80. J. Dispersion Sci. Technol. 2016;37:1511-1517.
Not in our library
64.
de la Maza A., Coderch L., Lopez O., Baucells J., Parra J.L. Permeability changes caused by surfactants in liposomes that model the stratum corneum lipid composition. J. Am. Oil Chem. Soc. 1997;74:1-8.
Not in our library
65.
Gangwar M., Singh R., Goel R.K., Nath G. Recent advances in various emerging vescicular systems: an overview. Asian Pac. J. Trop. Biomed. 2012;2:S1176-S1188.
Not in our library
66.
Paolino D., Cosco D., Cilurzo F., Trapasso E., Morittu V.M., Celia C., Fresta M. Improved in vitro and in vivo collagen biosynthesis by asiaticoside-loaded ultradeformable vesicles. J. Contr. Release: Off. J. Controll. Release Soc. 2012;162:143-151.
Not in our library10.1016/j.jconrel.2012.05.050
67.
Chen R., Li R., Liu Q., Bai C., Qin B., Ma Y. J. Han, ultradeformable liposomes: a novel vesicular carrier for enhanced transdermal delivery of procyanidins: effect of surfactants on the formation, stability, and transdermal delivery. AAPS PharmSciTech. 2017;18:1823-1832.
Not in our library10.1208/s12249-016-0661-5
68.
Souto E.B., Macedo A.S., Dias-Ferreira J., Cano A., Zielińska A., Matos C.M. Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (APIs). Int. J. Mol. Sci. 2021;22.
Not in our library10.3390/ijms22189743
69.
A.D. Bangham, M.W. Hill, N. Miller, Preparation and use of liposomes as models of biological membranes, Methods Member. Biol., Springer1974, pp. 1-68.
Not in our library
70.
Gonzalez-Rodriguez M., Rabasco A. Charged liposomes as carriers to enhance the permeation through the skin. Expet Opin. Drug Deliv. 2011;8:857-871.
Not in our library10.1517/17425247.2011.574610
71.
V. Torchilin, PEGylated Pharmaceutical Nanocarriers, Long Acting Injections and Implants, Springer2012, pp. 263-293.
Not in our library
72.
Sapra P., Tyagi P., Allen T.M. Ligand-targeted liposomes for cancer treatment. Curr. Drug Deliv. 2005;2:369-381.
Not in our library10.2174/156720105774370159
73.
Bibi S., Lattmann E., Mohammed A.R., Perrie Y. Trigger release liposome systems: local and remote controlled delivery? J. Microencapsul. 2012;29:262-276.
Not in our library10.3109/02652048.2011.646330
74.
Negishi Y., Ishii Y., Shiono H., Akiyama S., Sekine S., Kojima T., Mayama S., Kikuchi T., Hamano N., Endo-Takahashi Y., Suzuki R., Maruyama K., Aramaki Y. Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice. Mol. Pharm. 2014;11:1053-1061.
Not in our library10.1021/mp4004755
75.
Bangham A. A correlation between surface charge and coagulant action of phospholipids. Nature. 1961;192:1197-1198.
Not in our library10.1038/1921197a0
76.
Wu H., Yu M., Miao Y., He S., Dai Z., Song W., Liu Y., Song S., Ahmad E., Wang D., Gan Y. Cholesterol-tuned liposomal membrane rigidity directs tumor penetration and anti-tumor effect. Acta Pharm. Sin. B. 2019;9:858-870.
Not in our library10.1016/j.apsb.2019.02.010
77.
Kaddah S., Khreich N., Kaddah F., Charcosset C., Greige-Gerges H. Cholesterol modulates the liposome membrane fluidity and permeability for a hydrophilic molecule. Food Chem. Toxicol. 2018;113:40-48.
Not in our library10.1016/j.fct.2018.01.017
78.
Jovanović A., Balanč B., Pravilović R., Ota A., Ulrih N., Nedović V., Branko B. 2017.
Not in our library
79.
Ceh B., Winterhalter M., Frederik P.M., Vallner J.J., Lasic D.D. Stealth® liposomes: from theory to product. Adv. Drug Deliv. Rev. 1997;24:165-177.
Not in our library
80.
Senior J., Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci. 1982;30:2123-2136.
Not in our library10.1016/0024-3205(82)90455-6
81.
Zhang J.-X., Wang K., Mao Z.-F., Fan X., Jiang D.-L., Chen M., Cui L., Sun K., Dang S.-C. Application of liposomes in drug development—focus on gastroenterological targets. Int. J. Nanomed. 2013;8:1325.
Not in our library10.2147/ijn.s42153
82.
Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. Activity of amphipathic poly (ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta Biomembr. 1991;1062:142-148.
Not in our library10.1016/0005-2736(91)90385-l
83.
San H., Yang Z.-Y., Pompili V.J., Jaffe M.L., Plautz G.E., Xu L., Felgner J.H., Wheeler C.J., Felgner P.L., Gao X. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum. Gene Ther. 1993;4:781-788.
Not in our library10.1089/hum.1993.4.6-781
84.
Majzoub R.N., Ewert K.K., Safinya C.R. Physical, E. Sciences, Cationic liposome–nucleic acid nanoparticle assemblies with applications in gene delivery and gene silencing. Math. Phys. Eng. Sci. 2016;374:20150129.
Not in our library10.1098/rsta.2015.0129
85.
Dass C.R. Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. Int. J. Pharm. 2003;267:1-12.
Not in our library10.1016/j.ijpharm.2003.08.010
86.
F. Lai, M. Schlich, C. Sinico, A.M. Fadda, Liposomes as Brain Targeted Delivery Systems, Nanomedicines for Brain Drug Delivery, Springer2021, pp. 29-59.
Not in our library
87.
Youn P., Chen Y., Furgeson D.Y. A myristoylated cell-penetrating peptide bearing a transferrin receptor-targeting sequence for neuro-targeted siRNA delivery. Mol. Pharm. 2014;11:486-495.
Not in our library10.1021/mp400446v
88.
Hervé F., Ghinea N., Scherrmann J.-M. CNS delivery via adsorptive transcytosis. AAPS J. 2008;10:455-472.
Not in our library10.1208/s12248-008-9055-2
89.
Mc Carthy D.J., Malhotra M., O’Mahony A.M., Cryan J.F., O’Driscoll C.M. Nanoparticles and the blood-brain barrier: advancing from in-vitro models towards therapeutic significance. Pharmaceut. Res. 2015;32:1161-1185.
Not in our library10.1007/s11095-014-1545-6
90.
Knudsen K.B., Northeved H., Ek P.K., Permin A., Gjetting T., Andresen T.L., Larsen S., Wegener K.M., Lykkesfeldt J., Jantzen K.J.N.N. In vivo toxicity of cationic micelles and liposomes. 2015;11:467-477.
Not in our library10.1016/j.nano.2014.08.004
91.
Semple S.C., Chonn A., Cullis P.R. Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv. Drug Deliv. Rev. 1998;32:3-17.
Not in our library10.1016/s0169-409x(97)00128-2
92.
Suk J.S., Xu Q., Kim N., Hanes J., Ensign L.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 2016;99:28-51.
Not in our library10.1016/j.addr.2015.09.012
93.
Gregoriadis G., Neerunjun D.E. Control of the rate of hepatic uptake and catabolism of liposome-entrapped proteins injected into rats. Possible therapeutic applications. Eur. J. Biochem. 1974;47:179-185.
Not in our library10.1111/j.1432-1033.1974.tb03681.x
94.
Gonzalez-Rodriguez M., Rabasco A. Charged liposomes as carriers to enhance the permeation through the skin. Expet Opin. Drug Deliv. 2011;8:857-871.
Not in our library10.1517/17425247.2011.574610
95.
Rangger C., Helbok A., von Guggenberg E., Sosabowski J., Radolf T., Prassl R., Andreae F., Thurner G.C., Haubner R., Decristoforo C. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles. Int. J. Nanomed. 2012;7:5889.
Not in our library10.2147/ijn.s36847
96.
Sunamoto J., Iwamoto K. Protein-coated and polysaccharide-coated liposomes as drug carriers. J. Crit. Rev. Therapeut. Drug Carr. Syst. 1986;2:117-136.
Not in our library
97.
Allen T. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system. J. Adv. Drug Deliv. Rev. 1994;13:285-309.
Not in our library
98.
Paolino D., Cosco D., Racanicchi L., Trapasso E., Celia C., Iannone M., Puxeddu E., Costante G., Filetti S., Russo D., Fresta M. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. J. Contr. Release: Off. J. Controll. Release Soc. 2010;144:144-150.
Not in our library10.1016/j.jconrel.2010.02.021
99.
He K., Tang M.J.C.-b.i. Safety of novel liposomal drugs for cancer treatment. Adv. Prosp. 2018;295:13-19.
Not in our library10.1016/j.cbi.2017.09.006
100.
Vaage J., Donovan D., Mayhew E., Abra R., Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 1993;72:3671-3675.
Not in our library10.1002/1097-0142(19931215)72:12<3671::aid-cncr2820721219>3.0.co;2-u
101.
Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013;65:36-48.
Not in our library10.1016/j.addr.2012.09.037
102.
Leserman L.D., Weinstein J.N., Blumenthal R., Terry W.D. Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells. Proc. Natl. Acad. Sci. U. S. A. 1980;77:4089-4093.
Not in our library10.1073/pnas.77.7.4089
103.
Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expet Opin. Drug Deliv. 2011;8:565-580.
Not in our library10.1517/17425247.2011.566552
104.
Alshaer W., Hillaireau H., Vergnaud J., Ismail S., Fattal E. Functionalizing liposomes with anti-CD44 aptamer for selective targeting of cancer cells. Bioconjugate Chem. 2015;26:1307-1313.
Not in our library10.1021/bc5004313
105.
Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Adv. Drug Deliv. Rev. 2000;43:197-205.
Not in our library10.1016/s0169-409x(00)00069-7
106.
d'Avanzo N., Torrieri G., Figueiredo P., Celia C., Paolino D., Correia A., Moslova K., Teesalu T., Fresta M., Santos H.A. LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy. Int. J. Pharm. 2021;597:120346.
Not in our library10.1016/j.ijpharm.2021.120346
107.
Paolino D., Cosco D., Gaspari M., Celano M., Wolfram J., Voce P., Puxeddu E., Filetti S., Celia C., Ferrari M., Russo D., Fresta M. Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes. Biomaterials. 2014;35:7101-7109.
Not in our library10.1016/j.biomaterials.2014.04.088
108.
Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers, Nature reviews. Drug Discov. 2005;4:145-160.
Not in our library10.1038/nrd1632
109.
Gabizon A.A., Shmeeda H., Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 2006;16:175-183.
Not in our library10.1080/08982100600848769
110.
Rezler E.M., Khan D.R., Lauer-Fields J., Cudic M., Baronas-Lowell D., Fields G.B. Targeted drug delivery utilizing protein-like molecular architecture. J. Am. Chem. Soc. 2007;129:4961-4972.
Not in our library10.1021/ja066929m
111.
Koren E., Apte A., Jani A., Torchilin V.P. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J. Contr. Release: Off. J. Controll. Release Soc. 2012;160:264-273.
Not in our library10.1016/j.jconrel.2011.12.002
112.
Zhou X., Zhang M., Yung B., Li H., Zhou C., Lee L.J., Lee R.J. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int. J. Nanomed. 2012;7:5465-5474.
Not in our library10.2147/ijn.s33965
113.
Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006;66:6732-6740.
Not in our library10.1158/0008-5472.can-05-4199
114.
Nellis D.F., Giardina S.L., Janini G.M., Shenoy S.R., Marks J.D., Tsai R., Drummond D.C., Hong K., Park J.W., Ouellette T.F., Perkins S.C., Kirpotin D.B. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol. Prog. 2005;21:221-232.
Not in our library10.1021/bp049839z
115.
Suzuki R., Takizawa T., Kuwata Y., Mutoh M., Ishiguro N., Utoguchi N., Shinohara A., Eriguchi M., Yanagie H., Maruyama K. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int. J. Pharm. 2008;346:143-150.
Not in our library10.1016/j.ijpharm.2007.06.010
116.
Jaracz S., Chen J., Kuznetsova L.V., Ojima I. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg. Med. Chem. 2005;13:5043-5054.
Not in our library10.1016/j.bmc.2005.04.084
117.
Jin E., Zhang B., Sun X., Zhou Z., Ma X., Sun Q., Tang J., Shen Y., Van Kirk E., Murdoch W.J., Radosz M. Acid-active cell-penetrating peptides for in vivo tumor-targeted drug delivery. J. Am. Chem. Soc. 2013;135:933-940.
Not in our library10.1021/ja311180x
118.
Jiang F., Liu B., Lu J., Li F., Li D., Liang C., Dang L., Liu J., He B., Badshah S.A., Lu C., He X., Guo B., Zhang X.B., Tan W., Lu A., Zhang G. Progress and challenges in developing aptamer-functionalized targeted drug delivery systems. Int. J. Mol. Sci. 2015;16:23784-23822.
Not in our library10.3390/ijms161023784
119.
Nsairat H., Mahmoud I.S., Odeh F., Abuarqoub D., Al-Azzawi H., Zaza R., Qadri M.I., Ismail S., Al Bawab A., Awidi A., Alshaer W. Grafting of anti-nucleolin aptamer into preformed and remotely loaded liposomes through aptamer-cholesterol post-insertion. RSC Adv. 2020;10:36219-36229.
Not in our library10.1039/d0ra07325c
120.
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies · 2019
No notice
121.
Gupta S., Gupta M.K. Possible role of nanocarriers in drug delivery against cervical cancer. Nano Rev. Exp. 2017;8:1335567.
Not in our library10.1080/20022727.2017.1335567
122.
Backer M.V., Gaynutdinov T.I., Patel V., Jehning B.T., Myshkin E., Backer J.M. Adapter protein for site-specific conjugation of payloads for targeted drug delivery. Bioconjugate Chem. 2004;15:1021-1029.
Not in our library10.1021/bc0499477
123.
Chau Y., Tan F.E., Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjugate Chem. 2004;15:931-941.
Not in our library10.1021/bc0499174
124.
Bertrand N., Leroux J.C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J. Contr. Release: Off. J. Controll. Release Soc. 2012;161:152-163.
Not in our library10.1016/j.jconrel.2011.09.098
125.
Mura S., Nicolas J., Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013;12:991-1003.
Not in our library10.1038/nmat3776
126.
Lee Y., Thompson D.H. 2017;9.
Not in our library10.1002/wnan.1450
127.
Stimuli-Responsive Nanomaterials for Application in Antitumor Therapy and Drug Delivery · 2020
No notice
128.
Rayamajhi S., Marchitto J., Nguyen T.D.T., Marasini R., Celia C., Aryal S. pH-responsive cationic liposome for endosomal escape mediated drug delivery. Colloids Surf. B Biointerfaces. 2020;188:110804.
Not in our library10.1016/j.colsurfb.2020.110804
129.
Paliwal S.R., Paliwal R., Vyas S.P. A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery. Drug Deliv. 2015;22:231-242.
Not in our library10.3109/10717544.2014.882469
130.
Wang Y., Shim M.S., Levinson N.S., Sung H.W., Xia Y. Stimuli-responsive materials for controlled release of theranostic agents. Adv. Funct. Mater. 2014;24:4206-4220.
Not in our library10.1002/adfm.201400279
131.
Yavlovich A., Smith B., Gupta K., Blumenthal R., Puri A. Light-sensitive lipid-based nanoparticles for drug delivery: design principles and future considerations for biological applications. Mol. Membr. Biol. 2010;27:364-381.
Not in our library10.3109/09687688.2010.507788
132.
Gai S., Yang G., Yang P., He F., Lin J., Jin D., Xing B. Recent advances in functional nanomaterials for light–triggered cancer therapy. Nano Today. 2018;19:146-187.
Not in our library
133.
Mills J.K., Needham D. Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochim. Biophys. Acta Biomembr. 2005;1716:77-96.
Not in our library10.1016/j.bbamem.2005.08.007
134.
Ta T., Porter T.M. Thermosensitive liposomes for localized delivery and triggered release of chemotherapy. J. Contr. Release. 2013;169:112-125.
Not in our library10.1016/j.jconrel.2013.03.036
135.
Chu K.F., Dupuy D.E. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer. 2014;14:199-208.
Not in our library10.1038/nrc3672
136.
Nardecchia S., Sánchez-Moreno P., Vicente J.d., Marchal J.A., Boulaiz H. Clinical trials of thermosensitive nanomaterials: an overview. Nanomaterials. 2019;9:191.
Not in our library10.3390/nano9020191
137.
Pezzoli D., Tallarita E., Rosini E., Candiani G. Characterization and investigation of redox-sensitive liposomes for gene delivery. Methods Mol. Biol. 2016;1445:217-233.
Not in our library10.1007/978-1-4939-3718-9_14
138.
Ong W., Yang Y., Cruciano A.C., McCarley R.L. Redox-Triggered contents release from liposomes. J. Am. Chem. Soc. 2008;130:14739-14744.
Not in our library10.1021/ja8050469
139.
Antoniou A.I., Giofrè S., Seneci P., Passarella D., Pellegrino S. Stimulus-responsive liposomes for biomedical applications. Drug Discov. Today. 2021;26:1794-1824.
Not in our library10.1016/j.drudis.2021.05.010
140.
Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery · 2020
No notice
141.
Lou J., Best M.D. A general approach to enzyme-responsive liposomes. Chemistry. 2020;26:8597-8607.
Not in our library10.1002/chem.202000529
142.
Chu C.-J., Szoka F.C. pH-Sensitive Liposomes. J. Liposome Res. 1994;4:361-395.
Not in our library
143.
Karanth H., Murthy R.S. pH-sensitive liposomes--principle and application in cancer therapy. J. Pharm. Pharmacol. 2007;59:469-483.
Not in our library10.1211/jpp.59.4.0001
144.
Lafi Z., Alshaer W., Hatmal M.m.M., Zihlif M., Alqudah D.A., Nsairat H., Azzam H., Aburjai T., Bustanji Y., Awidi A. Aptamer-functionalized pH-sensitive liposomes for a selective delivery of echinomycin into cancer cells. RSC Adv. 2021;11:29164-29177.
Not in our library10.1039/d1ra05138e
145.
Katsuji S., Nobuki K., Katsuyuki Y., Ryo S., Kazuo M. 2008;1675-1678.
Not in our library
146.
Sun C., sciences p. 2017;1290-1314.
Not in our library
147.
Mahanty A., Li Y., Yu Y., Banerjee P., Chaurasiya B., Tu J., Sun C. 2017;1290-1314.
Not in our library
148.
Bhupendra P., Narendra K., Suman S., Amit R. Liposome: method of preparation, advantages, evaluation and its application. J. Appl. Pharmaceut. Res. 2015;3:1-8.
Not in our library
149.
Shi N.-Q., Qi X.-R., Lu W.-L., Qi X.-R. Liposome-Based Drug Delivery Systems. 2017;1-10.
Not in our library
150.
Szoka F., Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu. Rev. Biophys. Bioeng. 1980;9:467-508.
Not in our library10.1146/annurev.bb.09.060180.002343
151.
Has C., Sunthar P. A comprehensive review on recent preparation techniques of liposomes. J. Liposome Res. 2020;30:336-365.
Not in our library10.1080/08982104.2019.1668010
152.
Szoka F., Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad. Sci. U. S. A. 1978;75:4194-4198.
Not in our library10.1073/pnas.75.9.4194
153.
Jaafar-Maalej C., Charcosset C., Fessi H. A new method for liposome preparation using a membrane contactor. J. Liposome Res. 2011;21:213-220.
Not in our library10.3109/08982104.2010.517537
154.
Maherani B., Arab-Tehrany E., Mozafari M., Gaiani C., M L. Liposomes: a review of manufacturing techniques and targeting strategies. Curr. Nanosci. 2011;7:436-452.
Not in our library
155.
Vemuri S., Rhodes C.T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm. Acta Helv. 1995;70:95-111.
Not in our library10.1016/0031-6865(95)00010-7
156.
Jiskoot W., Teerlink T., Beuvery E.C., Crommelin D.J. Preparation of liposomes via detergent removal from mixed micelles by dilution. The effect of bilayer composition and process parameters on liposome characteristics. Pharm. Weekbl. - Sci. Ed. 1986;8:259-265.
Not in our library10.1007/bf01960070
157.
Milsmann M.H.W., Schwendener R.A., Weder H.-G. The preparation of large single bilayer liposomes by a fast and controlled dialysis. Biochim. Biophys. Acta Biomembr. 1978;512:147-155.
Not in our library10.1016/0005-2736(78)90225-0
158.
Schwendener R.A., Asanger M., Weder H.G. n-alkyl-glucosides as detergents for the preparation of highly homogeneous bilayer liposomes of variable sizes (60–240 nm φ) applying defined rates of detergent removal by dialysis. Biochem. Biophys. Res. Commun. 1981;100:1055-1062.
Not in our library10.1016/0006-291x(81)91930-6
159.
Enoch H.G., Strittmatter P. Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. Proc. Natl. Acad. Sci. Unit. States Am. 1979;76:145.
Not in our library10.1073/pnas.76.1.145
160.
Ueno M., Tanford C., Reynolds J.A. Phospholipid vesicle formation using nonionic detergents with low monomer solubility. Kinetic factors determine vesicle size and permeability. Biochemistry. 1984;23:3070-3076.
Not in our library10.1021/bi00308a034
161.
Schurtenberger P., Mazer N., Waldvogel S., Känzig W. Preparation of monodisperse vesicles with variable size by dilution of mixed micellar solutions of bile salt and phosphatidylcholine. Biochim. Biophys. Acta Biomembr. 1984;775:111-114.
Not in our library10.1016/0005-2736(84)90241-4
162.
Schubert R. 2003;46-70.
Not in our library10.1016/s0076-6879(03)67005-9
163.
Shew R.L., Deamer D.W. A novel method for encapsulation of macromolecules in liposomes. Biochim. Biophys. Acta Biomembr. 1985;816:1-8.
Not in our library10.1016/0005-2736(85)90386-4
164.
Visht S., Awasthi R., Rai R., Srivastav P. Development of dehydration-rehydration liposomal system using film hydration technique followed by sonication. Curr. Drug Deliv. 2014;11:763-770.
Not in our library10.2174/1567201811666140910122945
165.
Mozafari M.R. Liposomes: an overview of manufacturing techniques. Cell. Mol. Biol. Lett. 2005;10:711-719.
Not in our library
166.
Mozafari M. 2005;91-98.
Not in our library
167.
Gutman M. The pH jump: probing of macromolecules and solutions by a laser-induced, ultrashort proton pulse--theory and applications in biochemistry. Methods Biochem. Anal. 1984;30:1-103.
Not in our library10.1002/9780470110515.ch1
168.
Genç R., Ortiz M., O′Sullivan C.K. Curvature-Tuned preparation of nanoliposomes. Langmuir. 2009;25:12604-12613.
Not in our library10.1021/la901789h
169.
Hauser H., Gains N. Spontaneous vesiculation of phospholipids: a simple and quick method of forming unilamellar vesicles. Proc. Natl. Acad. Sci. Unit. States Am. 1982;79:1683.
Not in our library10.1073/pnas.79.6.1683
170.
Yu B., Lee R.J., Lee L.J. Microfluidic methods for production of liposomes. Methods Enzymol. 2009;465:129-141.
Not in our library10.1016/s0076-6879(09)65007-2
171.
Liposome production by microfluidics: potential and limiting factors · 2016
No notice
172.
Gkionis L., Aojula H., Harris L.K., Tirella A. Microfluidic-assisted fabrication of phosphatidylcholine-based liposomes for controlled drug delivery of chemotherapeutics. Int. J. Pharm. 2021;604:120711.
Not in our library10.1016/j.ijpharm.2021.120711
173.
William B., Noémie P., Brigitte E., Géraldine P. Supercritical fluid methods: an alternative to conventional methods to prepare liposomes. Chem. Eng. J. 2020;383:123106.
Not in our library
174.
Bigazzi W., Penoy N., Evrard B., Piel G. Supercritical fluid methods: an alternative to conventional methods to prepare liposomes. Chem. Eng. J. 2019;383:123106.
Not in our library
175.
Pick U. Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures. Arch. Biochem. Biophys. 1981;212:186-194.
Not in our library10.1016/0003-9861(81)90358-1
176.
Liu L., Yonetani T. Preparation and characterization of liposome-encapsulated haemoglobin by a freeze-thaw method. J. Microencapsul. 1994;11:409-421.
Not in our library10.3109/02652049409034258
177.
El-Nesr O.H., Yahiya S.A., El-Gazayerly O.N. Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes. Saudi Pharmaceut. J. 2010;18:217-224.
Not in our library10.1016/j.jsps.2010.07.003
178.
Lyophilization of Liposomal Formulations: Still Necessary, Still Challenging · 2018
No notice
179.
Mahmood S., Mandal U.K., Chatterjee B., Taher M. Advanced characterizations of nanoparticles for drug delivery: investigating their properties through the techniques used in their evaluations. Nanotechnol. Rev. 2017;6:355-372.
Not in our library
180.
Mourdikoudis S., Pallares R.M., Thanh N.T.K. Characterization techniques for nanoparticles: comparison and complementarity upon studying nanoparticle properties. Nanoscale. 2018;10:12871-12934.
Not in our library10.1039/c8nr02278j
181.
Senn A., Pilet P.-E. Electrophoretic mobility, zeta potential and surface charges of maize root protoplasts. Z. Pflanzenphysiol. 1981;102:19-32.
Not in our library
182.
Zhao Z., Katai H., Higashi K., Ueda K., Kawakami K., Moribe K. Cryo-TEM and AFM observation of the time-dependent evolution of amorphous probucol nanoparticles formed by the aqueous dispersion of ternary solid dispersions. Mol. Pharm. 2019;16:2184-2198.
Not in our library10.1021/acs.molpharmaceut.9b00158
183.
Byrn S., Zografi G., Chen X. 2017;124-141.
Not in our library
184.
Clout A., Buanz A.B.M., Prior T.J., Reinhard C., Wu Y., O’Hare D., Williams G.R., Gaisford S. Simultaneous differential scanning calorimetry-synchrotron X-ray powder diffraction: a powerful technique for physical form characterization in pharmaceutical materials. Anal. Chem. 2016;88:10111-10117.
Not in our library10.1021/acs.analchem.6b02549
185.
Panwar P., Pandey B., Lakhera P.C., Singh K.P. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int. J. Nanomed. 2010;5:101-108.
Not in our library10.2147/ijn.s8030
186.
Wallace S.J., Li J., Nation R.L., Boyd B.J. Drug release from nanomedicines: selection of appropriate encapsulation and release methodology. Drug Deliv. Transl. Res. 2012;2:284-292.
Not in our library10.1007/s13346-012-0064-4
187.
Hwang S.H., Maitani Y., Qi X.R., Takayama K., Nagai T. Remote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods. Int. J. Pharm. 1999;179:85-95.
Not in our library10.1016/s0378-5173(98)00392-5
188.
Ascenso A., Cruz M., Euleterio C., Carvalho F.A., Santos N.C., Marques H.C., Simoes S. Novel tretinoin formulations: a drug-in-cyclodextrin-in-liposome approach. J. Liposome Res. 2013;23:211-219.
Not in our library10.3109/08982104.2013.788026
189.
Deng Y., Ling J., Li M.H. Physical stimuli-responsive liposomes and polymersomes as drug delivery vehicles based on phase transitions in the membrane. Nanoscale. 2018;10:6781-6800.
Not in our library10.1039/c8nr00923f
190.
Zhang L., Zhang Q., Wang X., Zhang W., Lin C., Chen F., Yang X., Pan W. Drug-in-cyclodextrin-in-liposomes: a novel drug delivery system for flurbiprofen. Int. J. Pharm. 2015;492:40-45.
Not in our library10.1016/j.ijpharm.2015.07.011
191.
Fenske D.B., Cullis P.R. Liposomal nanomedicines. Expet Opin. Drug Deliv. 2008;5:25-44.
Not in our library10.1517/17425247.5.1.25
192.
Odeh F., Nsairat H., Alshaer W., Alsotari S., Buqaien R., Ismail S., Awidi A., Al Bawab A. Remote loading of curcumin-in-modified β-cyclodextrins into liposomes using a transmembrane pH gradient. RSC Adv. 2019;9:37148-37161.
Not in our library10.1039/c9ra07560g
193.
Sur S., Fries A.C., Kinzler K.W., Zhou S., Vogelstein B. Remote loading of preencapsulated drugs into stealth liposomes. Proc. Natl. Acad. Sci. U. S. A. 2014;111:2283-2288.
Not in our library10.1073/pnas.1324135111
194.
Drummond D.C., Noble C.O., Guo Z., Hong K., Park J.W., Kirpotin D.B. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271-3277.
Not in our library10.1158/0008-5472.can-05-4007
195.
Bolotin E.M., Cohen R., Bar L.K., Emanuel N., Ninio S., Barenholz Y., Lasic D.D. Ammonium sulfate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J. Liposome Res. 1994;4:455-479.
Not in our library
196.
Madden T.D., Harrigan P.R., Tai L.C., Bally M.B., Mayer L.D., Redelmeier T.E., Loughrey H.C., Tilcock C.P., Reinish L.W., Cullis P.R. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem. Phys. Lipids. 1990;53:37-46.
Not in our library10.1016/0009-3084(90)90131-a
197.
V Zhigaltsev I., Winters G., Srinivasulu M., Crawford J., Wong M., Amankwa L., Waterhouse D., Masin D., Webb M., Harasym N., Heller L., Bally M.B., Ciufolini M.A., Cullis P.R., Maurer N. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J. Contr. Release: Off. J. Controll. Release Soc. 2010;144:332-340.
Not in our library10.1016/j.jconrel.2010.02.029
198.
Alshaer W., Zraikat M., Amer A., Nsairat H., Lafi Z., Alqudah D.A., Al Qadi E., Alsheleh T., Odeh F., Alkaraki A., Zihlif M., Bustanji Y., Fattal E., Awidi A. Encapsulation of echinomycin in cyclodextrin inclusion complexes into liposomes: in vitro anti-proliferative and anti-invasive activity in glioblastoma. RSC Adv. 2019;9:30976-30988.
Not in our library10.1039/c9ra05636j
199.
Liposomal Drug Delivery Systems and Anticancer Drugs · 2018
No notice
200.
Interplay of protein corona and immune cells controls blood residency of liposomes · 2019
Corrected
201.
Palchetti S., Caputo D., Digiacomo L., Capriotti A.L., Coppola R., Pozzi D., Caracciolo G. Protein corona fingerprints of liposomes: new opportunities for targeted drug delivery and early detection in pancreatic cancer. Pharmaceutics. 2019;11:31.
Not in our library10.3390/pharmaceutics11010031
202.
Digiacomo L., Giulimondi F., Pozzi D., Coppola A., La Vaccara V., Caputo D., Caracciolo G. A proteomic study on the personalized protein corona of liposomes. Relevance for early diagnosis of pancreatic DUCTAL adenocarcinoma and biomarker detection. J. Nanotheran. 2021;2:82-93.
Not in our library
203.
Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery · 2018
No notice
204.
Cabanes A., Even-Chen S., Zimberoff J., Barenholz Y., Kedar E., Gabizon A. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2, Clinical cancer research. Off. J. Am. Assoc. Canc. Res. 1999;5:687-693.
Not in our library
205.
Fukuda A., Tahara K., Hane Y., Matsui T., Sasaoka S., Hatahira H., Motooka Y., Hasegawa S., Naganuma M., Abe J., Nakao S., Takeuchi H., Nakamura M. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS One. 2017;12.
Not in our library10.1371/journal.pone.0185654
206.
Angst M.S., Drover D.R. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin. Pharmacokinet. 2006;45:1153-1176.
Not in our library10.2165/00003088-200645120-00002
207.
Chou H., Lin H., Liu J.M. A tale of the two PEGylated liposomal doxorubicins. OncoTargets Ther. 2015;8:1719-1720.
Not in our library10.2147/ott.s79089
208.
Fassas A., Anagnostopoulos A. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk. Lymphoma. 2005;46:795-802.
Not in our library10.1080/10428190500052438
209.
Batist G., Barton J., Chaikin P., Swenson C., Welles L. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expet Opin. Pharmacother. 2002;3:1739-1751.
Not in our library10.1517/14656566.3.12.1739
210.
Murry D.J., Blaney S.M. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann. Pharmacother. 2000;34:1173-1178.
Not in our library10.1345/aph.19347
211.
Meyers P.A., Chou A.J. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. Adv. Exp. Med. Biol. 2014;804:307-321.
Not in our library10.1007/978-3-319-04843-7_17
212.
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine · 2012
No notice
213.
Passero F.C., Grapsa D., Syrigos K.N., Saif M.W. The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expet Rev. Anticancer Ther. 2016;16:697-703.
Not in our library10.1080/14737140.2016.1192471
214.
Krauss A.C., Gao X., Li L., Manning M.L., Patel P., Fu W., Janoria K.G., Gieser G., Bateman D.A., Przepiorka D., Shen Y.L., Shord S.S., Sheth C.M., Banerjee A., Liu J., Goldberg K.B., Farrell A.T., Blumenthal G.M., Pazdur R. FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia. Clin. Cancer Res.: Off. J. Am. Assoc. Canc. Res. 2019;25:2685-2690.
Not in our library10.1158/1078-0432.ccr-18-2990
215.
Koudelka S., Turánek J. Liposomal paclitaxel formulations. J. Contr. Release: Off. J. Controll. Release Soc. 2012;163:322-334.
Not in our library10.1016/j.jconrel.2012.09.006
216.
Azanza J.R., Sádada B., Reis J. Liposomal formulations of amphotericin B: differences according to the scientific evidence. Rev. Española Quimioter.: Pub. Ofic. Soc. Espan. Quimioter. 2015;28:275-281.
Not in our library
217.
Ostrosky-Zeichner L., Marr K.A., Rex J.H., Cohen S.H. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2003;37:415-425.
Not in our library10.1086/376634
218.
Romero E.L., Morilla M.J. Drug delivery systems against leishmaniasis? Still an open question. Expet Opin. Drug Deliv. 2008;5:805-823.
Not in our library10.1517/17425247.5.7.805
219.
Rudramurthy S.M., Jatana M., Singh R., Chakrabarti A. In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole. Mycoses. 2013;56:39-46.
Not in our library10.1111/j.1439-0507.2012.02197.x
220.
Chang H.I., Yeh M.K. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomed. 2012;7:49-60.
Not in our library10.2147/ijn.s26766
221.
Alfayez M., Kantarjian H., Kadia T., Ravandi-Kashani F., Daver N. CPX-351 (vyxeos) in AML. Leuk. Lymphoma. 2020;61:288-297.
Not in our library10.1080/10428194.2019.1660970
222.
McAlvin J.B., Padera R.F., Shankarappa S.A., Reznor G., Kwon A.H., Chiang H.H., Yang J., Kohane D.S. Multivesicular liposomal bupivacaine at the sciatic nerve. Biomaterials. 2014;35:4557-4564.
Not in our library10.1016/j.biomaterials.2014.02.015
223.
Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006;1:297-315.
Not in our library
224.
Gregoriadis G. Liposomes and mRNA: two technologies together create a COVID-19 vaccine. Med. Drug Discov. 2021;12:100104.
Not in our library
225.
A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study · 2021
Not checked
226.
Constantin C., Pisani A., Bardi G., Neagu M. Nano-carriers of COVID-19 vaccines: the main pillars of efficacy. Nanomedicine. 2021;16:2377-2387.
Not in our library10.2217/nnm-2021-0250

Cited by papers we hold 4

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape · 2025
No notice
A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity · 2024
No notice
Advances in Glioblastoma Therapy: An Update on Current Approaches · 2023
No notice
Liposomes for Tumor Targeted Therapy: A Review · 2023
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.